Please assess the completion status of the following clinical trial:

Trial Title: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older at the time of signing the informed consent.~* Female subject of non-childbearing potential or Male subject who is surgically sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').~* BMI equal to 30.0 kg/m\^2 or greater or BMI equal to 27.0 kg/m\^2 or greater with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension or dyslipidaemia (to be assessed at the investigator's discretion).~Exclusion Criteria:~* HbA1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central laboratory at screening.~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening irrespective of medical records.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NNC0174-0833, 4.5 mg (Type: EXPERIMENTAL): Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
- NNC0174-0833, 2.4 mg (Type: EXPERIMENTAL): Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
- NNC0174-0833, 1.2 mg (Type: EXPERIMENTAL): Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
- NNC0174-0833, 0.6 mg (Type: EXPERIMENTAL): Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
- NNC0174-0833 0.3 mg (Type: EXPERIMENTAL): Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
- Placebo 2.4 mg (NNC0174-0833) (Type: PLACEBO_COMPARATOR): Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
- Placebo 4.5 mg (NNC0174-0833) (Type: PLACEBO_COMPARATOR): Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
- Placebo 1.2 mg (NNC0174-0833) (Type: PLACEBO_COMPARATOR): Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
- Placebo 0.6 mg (NNC0174-0833) (Type: PLACEBO_COMPARATOR): Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
- Placebo 0.3 mg (NNC0174-0833) (Type: PLACEBO_COMPARATOR): Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
- Liraglutide 3.0 mg (Type: ACTIVE_COMPARATOR): Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
- Placebo 3.0 mg (Liraglutide) (Type: PLACEBO_COMPARATOR): Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete